Health
Immunotherapy extends survival in patients with advanced bladder cancer – News-Medical.Net
An immunotherapy drug called ‘avelumab’ has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial led by Queen Mary University of London and Barts Cancer Cent…
Reviewed by Emily Henderson, B.Sc.Sep 18 2020
An immunotherapy drug called ‘avelumab’ has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial led by Queen Mary University of London and Barts Cancer Centre, UK.
This is the first time an immune therapy has resulted in a survival advantage in this setting in bladder cancer, and will potentially benefit thousands of patients each year.
The resul…
-
General21 hours agoAbattoir worker in serious condition after workplace accident in Echuca
-
General21 hours agoWoman who reported NSW MP Gareth Ward’s alleged sex crimes cross-examined
-
Noosa News11 hours agoFull house as Minister shares vision for Sunshine Coast transport
-
Noosa News22 hours agoWoman charged with Pheobe Bishop’s murder to face all charges in court later this year